Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | HPD | P32754 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865354 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1MAPTKDM4EGAA | |
| SCHEMBL6868637 | 0.84 | MAPT (0.56) | ALDH1A1MAPK1MAPTKDM4EGAA | |
| SCHEMBL6868632 | 0.84 | MAPT (0.56) | ALDH1A1MAPK1MAPTKDM4EGAA | |
| SCHEMBL13330216 | 0.79 | MAPT (0.50) | ALDH1A1MAPK1MAPTKDM4EGAA | |
| SCHEMBL12957532 | 0.78 | MAPT (0.53) | ALDH1A1MAPK1MAPTKDM4EGAA | |
| SCHEMBL8143004 | 0.76 | MAPK1 (0.56) | ALDH1A1MAPK1MAPTKDM4EGAA | |
| SCHEMBL8143007 | 0.76 | MAPK1 (0.56) | ALDH1A1MAPK1MAPTKDM4EGAA | |
| SCHEMBL6865307 | 0.76 | MAPT (0.51) | ALDH1A1MAPK1MAPTKDM4EGAA | |
| SCHEMBL6865301 | 0.76 | MAPT (0.51) | ALDH1A1MAPK1MAPTKDM4EGAA | |
| SCHEMBL4416018 | 0.74 | MAPK1 (0.57) | ALDH1A1MAPK1MAPTKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6815550-B2 | DIAZOTIZING A 5-PERFLUOROALKYL-O-NITROANILINE WITH SULFURIC ACID AND ALKALI METAL NITRITE OR NITROSYLSULFURIC ACID; COUPLING WITH A PHENOL; AND REDUCING THE MONOAZOBENZENE INTERMEDIATE TO THE CORRESPONDING 2H-BENZOTRIAZOLE | CIBA SPECIALTY CHEMICALS CORPORATION | 2004-11-09 | — | — | US | disclosed |
| US-6605727-B2 | Processes for the preparation of benzotriazole UV absorbers | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-08-12 | — | — | US | disclosed |
| US-20030130524-A1 | Processes for the preparation of benzotriazole UV absorbers | WOOD MERVIN G (US) | 2003-07-10 | — | — | US | disclosed |
| US-20030120083-A1 | Processes for the preparation of benzotriazole UV absorbers | WOOD MERVIN G (US) | 2003-06-26 | — | — | US | disclosed |
| US-6566507-B2 | Processes for the preparation of benzotriazole UV absorbers | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-05-20 | — | — | US | disclosed |
| EP-1305298-A2 | PROCESSES FOR THE PREPARATION OF BENZOTRIAZOLE UV ABSORBERS | Ciba SC Holding AG (CH) | 2003-05-02 | — | — | EP | disclosed |
| US-20020035175-A1 | Processes for the preparation of benzotriazole UV absorbers | CIBA SPECIALTY CHEMICALS CORP. | 2002-03-21 | — | — | US | disclosed |
| US-6353113-B1 | DIAZOTIZING THE PERFLUOROALKYL SUBSTITUTED O-NITROANILINE WITH SULFURIC ACID AND SODIUM NITRITE OR NITROSYLSULFURIC ACID TO FORM THE CORRESPONDING MONOAZOBENZENE INTERMEDIATE VIA THE DIAZONIUM SALT INTERMEDIATE WHICH IS THEN REDUCED | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-03-05 | — | — | US | disclosed |
| WO-2002012202-A2 | PROCESSES FOR THE PREPARATION OF BENZOTRIAZOLE UV ABSORBERS | CIBA SPECIALTY CHEMICALS HOLDINGS INC. (CH) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035175-A1 | Processes for the preparation of benzotriazole UV absorbers | SULT1A1, SULT2A1, NISCH | ALDH1A1 858/4885MAPK1 3004/4885MAPT 1737/4885 |
| US-20030120083-A1 | Processes for the preparation of benzotriazole UV absorbers | SULT1A1, SULT2A1, NISCH | ALDH1A1 858/4885MAPK1 3004/4885MAPT 1737/4885 |
| US-20030130524-A1 | Processes for the preparation of benzotriazole UV absorbers | SULT1A1, SULT2A1, NISCH | ALDH1A1 858/4885MAPK1 3004/4885MAPT 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.